Furthermore, tau-mediated neurodegeneration, which is independent with the Aβ pathway, has an additional impact on the pathological process of AD [33], which may be part of the reason why anti-Aβ therapies applied solely by only removing Aβ obviously from clinical AD patients were unable to improve or reverse the cognitive decline. This evidence concerns the gene MAPT and Alzheimer disease.